Researcher Resources

Who We Work With


Corrie Painter, PhD

Deputy Director, Count Me In

Broad Institute of MIT and Harvard

Working with the OSI has been one of the greatest honors of my professional career. As a sarcoma patient and as a cancer research scientist, I am committed to developing a comprehensive resource for the osteosarcoma community in order to drive discoveries and save lives. The sense of urgency that drives me is matched by everyone I’ve worked with at the OSI and I have faith that we will transform our understanding of this devastating disease.

Jonathan Bush, MD

Pediatric Pathologist, Department of
Pathology and Laboratory Medicine, University of British Columbia

Although unsuccessful in my first attempt, I received valuable and encouraging feedback that has prompted me to reach out to more collaborators and prepared a much more robust and exciting subsequent application.

Claudia Janda, PhD

Principal Investigator, Research Department at Princess Máxima Center for Pediatric Oncology

Although my proposed project was not funded, the application process was one of the most helpful and transparent I have observed. The feedback, to both for the LOI and the full applications, was very fair and helpful, and I really appreciate the time the committee took to think and comment on the project.

What We Fund


Clinical Trials

A clinical study with osteosarcoma patients is the culmination and ultimate test for often years of translational science work. We prioritze novel approaches that have strong preclinical rationales, and utilize an innovative trial model that allows a rapid readout of effectiveness.


Correlative Studies

Clinical trials are focused on determining whether an experimental therapy works so they usually do not include funding to study why the treatment does or does not work. Such correlative studies can add a valuable additional level of understanding to inform future development.


Translational Studies

Osteosarcoma is a complex, poorly understood cancer. We seek out projects that will generate seminal preclinical bilogicial insights and suggest new ways to attack the disease.

2022 Call for Letters of Intent

The Osteosarcoma Institute is now accepting Letters of Intent for the 2022 – 2023 funding cycle for clinical trials, correlative studies, and translational studies that will improve outcomes for recurrent osteosarcoma patients. We will accept submissions starting on September 1, 2022 and ending November 15, 2022 from both U.S. and international applicants.

Past Funded Work

Please see below for the Osteosarcoma Institute’s past funded work.

Blocking Osteosarcoma

Study conducted by Peter Scacheri, PhD, Member, GI Cancer Genetics Program, Case Comprehensive Cancer Center

Commenced February 2020, this laboratory study evaluates the potential role of new mechanisms to inhibit a gene required for cells to proliferate, called CDK4, to block the ability of osteosarcoma to metastasize.

($500,000 – Case Western Reserve University)

Revolutionizing Patient Support

Commenced April 2019, this was the initial investment to begin offering support and guidance through OSI Connect (formerly OSI Hotline) to patients, families, and physicians free of cost.

($128,000 – Honor Health Research Institute)

The Grant Process

The OSI funds grants in three osteosarcoma research areas:


Clinical trials of new potential therapies that have promising preclinical rationales


Correlative science – the evaluation of how and why a potential new therapy works, or doesn’t work, in clinical trials


The basic biology of osteosarcoma and its metastasis, looking for clues for how to attack it

Our principal grant mechanism involves an annual, two-stage process. In early fall, we issue a call for summary, letter of intent proposals in the three areas above.  In late fall, we convene expert review committees to evaluate these summary proposals and select finalists, who are invited to submit full, detailed proposals. The full proposals are evaluated, and grants are awarded in late spring. 

Because some projects may not fit in this timeline, we have a separate, ad-hoc procedure to consider “out-of-cycle” grants using the same criteria and standards. 

Read more about OSI’s off-cycle grant funding below. 


Discretionary Grants

OSI board members include physicians and basic science researchers who are continually introduced to innovative ideas and technologies at medical meetings and research conferences, or within the halls of their own institutions. If an intriguing idea is far enough along, its champion can be encouraged to apply for one of the main OSI grants. But often times such an idea is in a nascent stage and needs a relatively small but timely investment to establish its feasibility for further development in osteosarcoma. The OSI has established a discretionary grant program to pursue these opportunities. On the spot grants of up to $20,000 can be nimbly authorized by committees of OSI board members. To inquire about discretionary grants, please email a 1-2 page summary of your project to

Off-Cycle Requests

Our annual grant application window closes in mid-November. While our annual process constitutes the primary OSI grantmaking mechanism, we recognize that not all projects are compatible with that time frame; accordingly, we consider off-cycle proposals on a case-by-case basis. If you are interested in an out-of-cycle proposal, please contact us with a 1-2 page summary about your proposed project and include why it is time sensitive.

Before You Go

Sign-up for our newsletter and stay up-to-date about our fight against Osteosarcoma!

Translate »